Cargando…

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV

Epstein-Barr virus (EBV)-associated B cell lymphoproliferative disease (LPD) after hematopoietic stem cell or solid organ transplantation remains a life-threatening complication. Expression of the virus-encoded gene product, EBER, has been shown to prevent apoptosis via blockade of PKR activation. B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Pin-Yi, Currier, Mark A, Hansford, Loen, Kaplan, David, Chiocca, E. Antonio, Uchida, Hiroaki, Goins, William F., Cohen, Justus B., Glorioso, Joseph C., van Kuppevelt, Toin H., Mo, Xiaokui, Cripe, Timothy P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609913/ https://www.ncbi.nlm.nih.gov/pubmed/23254370 http://dx.doi.org/10.1038/gt.2012.93

Ejemplares similares

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
por: Leddon, Jennifer L, et al.
Publicado: (2015)

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles
por: Fu, Xinping, et al.
Publicado: (2018)

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
por: Jackson, Joseph W., et al.
Publicado: (2021)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
por: Sette, Paola, et al.
Publicado: (2019)

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes
por: Miyagawa, Yoshitaka, et al.
Publicado: (2017)

Novel mutations in U(L)24 and gH rescue efficient infection of an HSV vector retargeted to TrkA
por: Marzulli, Marco, et al.
Publicado: (2023)

STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
por: Kangas, Chase, et al.
Publicado: (2021)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
por: Koch, Marilin S., et al.
Publicado: (2020)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
por: Jahan, Nusrat, et al.
Publicado: (2021)

Engineered HSV vector achieves safe long-term transgene expression in the central nervous system
por: Verlengia, Gianluca, et al.
Publicado: (2017)

An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain
por: Reinhart, Bonnie, et al.
Publicado: (2016)

Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early Genes
por: Kuroda, Seiji, et al.
Publicado: (2020)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
por: Lifang, Yang, et al.
Publicado: (2008)

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability
por: Kennedy, Edward M., et al.
Publicado: (2020)

Assessment of IgG Antibodies Against HSV1, HSV2, CMV and EBV in Patients with Pemphigus Vulgaris Versus Healthy People
por: Ghalayani, Parichehr, et al.
Publicado: (2015)

MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats
por: Iida, Takafumi, et al.
Publicado: (2017)

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2013)

The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
por: Tang, Guijin, et al.
Publicado: (2023)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals
por: Dropulic, Lesia, et al.
Publicado: (2017)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Post-mortem detection of six human herpesviruses (HSV-1, HSV-2, VZV, EBV, CMV, HHV-6) in trigeminal and facial nerve ganglia by PCR
por: Ptaszyńska-Sarosiek, Iwona, et al.
Publicado: (2019)

Worldwide circulation of HSV-2 × HSV-1 recombinant strains
por: Koelle, David M., et al.
Publicado: (2017)

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
por: Tuzmen, Ceren, et al.
Publicado: (2020)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

Negative epidemiological association between HSV-1 and HSV-2 infections
por: Nasrallah, Gheyath K., et al.
Publicado: (2019)

Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
por: Hoang, Huy-Dung, et al.
Publicado: (2023)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
por: Gilbert, Peter B., et al.
Publicado: (2017)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability
por: Howard, Faith, et al.
Publicado: (2022)

Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV
por: Chiu, Christopher, et al.
Publicado: (2014)

In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease
por: Aubert, Martine, et al.
Publicado: (2014)

High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy
por: Sprague, Leslee, et al.
Publicado: (2018)

LAT Region Factors Mediating Differential Neuronal Tropism of HSV-1 and HSV-2 Do Not Act in Trans
por: Bertke, Andrea S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3b0u2m60497efsi4vits8o075g